Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients
Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients
复制标题
DOI：
10.1681/asn.2016070727
复制
发表时间：
2017-07-01
影响因子：
13.6
通讯作者：
Knechtle, Stuart
中科院分区：
文献类型：
--
作者：
Kwun, Jean;Burghuber, Christopher;Knechtle, Stuart
硼替佐米单药治疗具有预先形成的供体特异性抗体的肾移植候选人脱敏的疗效尚不清楚。我们评估了硼替佐米对通过完全不匹配的异体皮肤移植致敏的灵长类动物模型中预形成抗体和B细胞反应上游成分的影响，以提供有关使用硼替佐米作为脱敏手段的机制见解。静脉滴注硼替佐米治疗每周2次，持续1个月（每次剂量1.3 mg/m(2)），明显减少了骨髓中产生抗体的细胞和CD38(+)CD19(+)CD202浆细胞的数量(P
The efficacy of bortezomib monotherapy in desensitizing kidney transplant candidates with preformed donor-specific antibodies remains unclear. We evaluated the effect of bortezomib on preformed antibodies and upstream components of the B cell response in a primate model sensitized by fully mismatched allogeneic skin transplants to provide mechanistic insights regarding the use of bortezomib as a means of desensitization. Bortezomib treatment given intravenously twice weekly for 1 month (1.3 mg/m(2) per dose) clearly reduced the numbers of antibody-producing cells and CD38(+)CD19(+)CD202 plasma cells in the bone marrow (P